MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag158

Медицинская библиотека · The oncologist · 2026

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

Mascaró-Baselga Pau, Rodellar Sanz José Miguel, Nunes da Silva Tiago, Hernando Jorge, García-Álvarez Alejandro, González Merino Carlos, Molina-Cerrillo Javier, Fernandez-Pombo Antia, Iglesias-Alvarez German, Ceballos Lenza Isaac, Plana Serrahima María, Bella Cueto Maria Rosa, Isidro Maria Luisa, Martinez Trufero Javier, Marquina Gloria, Martinez Nieves, Crespo Guillermo, Jimeno Raquel, Lorenzo Isabel, Ayala de Miguel Pablo, Alcazar Victoria, Martínez-Badal Sandra, Capdevila Jaume, Alonso-Gordoa Teresa

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Anaplastic thyroid cancer (ATC) is an extremely rare cancer with very poor prognosis. Targeted therapies have improved outcomes in selected patients, but molecular testing is often difficult because of the aggressive course, rapid clinical deterioration, and long turnaround times. This study aimed to provide real-world evidence on the management and outcomes of ATC and to evaluate the prognostic impact of molecular testing.

MATERIALS AND

METHODS

This multicentric, retrospective study included patients diagnosed with ATC between 1992 and 2024 from the REGETNE-Thyroid Network. Factors associated with overall survival (OS) were analyzed using Cox proportional hazards models.

RESULTS

214 patients were included (median age 70.8 years; 56.5% female). Median OS was 4.5 months. Access to molecular testing (HR 0.42, p = 0.001) and BRAF V600E mutation (HR 0.50, p = 0.008) were associated with longer OS, whereas TERT promoter mutations were associated with shorter survival (HR 2.80, p = 0.014). Local surgery showed a favorable prognostic association, regardless of stage (IVa/IVb: HR 0.54, p = 0.026; IVc: HR 0.36, p < 0.001). In metastatic disease, immunotherapy (HR 0.31; p < 0.001), tyrosine kinase inhibitors (HR 0.40; p = 0.002) and their combination (HR 0.24; p = 0.001) significantly improved OS, whereas chemotherapy did not (HR 0.76; p = 0.096). Targeted therapy, used predominantly (>95%) in BRAF V600E-mutated ATC, was also associated with longer survival (HR 0.40; p = 0.001).

CONCLUSION

Molecular testing was associated with improved survival in ATC, likely driven by the identification of actionable alterations with effective targeted therapies. Local management is key in all stages. Our findings also support immunotherapy, tyrosine kinase inhibitors and their combinations as key therapeutic options.

Для цитирования: Mascaró-Baselga Pau, Rodellar Sanz José Miguel, Nunes da Silva Tiago, Hernando Jorge, García-Álvarez Alejandro, González Merino Carlos, Molina-Cerrillo Javier, Fernandez-Pombo Antia, Iglesias-Alvarez German, Ceballos Lenza Isaac, Plana Serrahima María, Bella Cueto Maria Rosa, Isidro Maria Luisa, Martinez Trufero Javier, Marquina Gloria, Martinez Nieves, Crespo Guillermo, Jimeno Raquel, Lorenzo Isabel, Ayala de Miguel Pablo, Alcazar Victoria, Martínez-Badal Sandra, Capdevila Jaume, Alonso-Gordoa Teresa. Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag158.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.